Drugs / Xinglou Chengqi granules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07163702 | Oct 2025 → Sep 2026 overdue | ischemic stroke | Dongzhimen Hospital, Beijing | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xinglou Chengqi granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07163702 ↗ |
| Route | Oral | “Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.” NCT07163702 ↗ |